Office of Technology Transfer – University of Michigan

Optoelectronic microprobe for tissue diagnostics

Technology #6217

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Optoelectronic microprobe for tissue diagnostics
Categories
Researchers
Mary-Ann Mycek
Managed By
Janani Ramaswamy
Patent Protection
US Patent Pending
Publications
Spectral areas and ratios classifier algorithm for pancreatic tissue classification using optical spectroscopy.
J Biomed Opt. 2010 Jan-Feb;15(1):010514. doi: 10.1117/1.3314900., 2010
Optical spectroscopy detects histological hallmarks of pancreatic cancer.
Opt Express. 2009 Sep 28;17(20):17502-16. doi: 10.1364/OE.17.017502., 2009
Probing pancreatic disease using tissue optical spectroscopy.
J Biomed Opt. 2007 Nov-Dec;12(6):060501. doi: 10.1117/1.2818029., 2007

Overview: Accurate pancreatic tissue classification for the diagnosis and differentiation of pancreatic andenocarcinoma and chronic pancreatitis

Background: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is commonly used to detect early-stage pancreatic adenocarcinomas, but is hindered by poor negative predictive value (cannot accurately exclude the presence of cancer) leading to delay, further testing and possibly unnecessary surgery. Furthermore, EUS-FNA is unable to consistently distinguish pancreatic adenocarcinoma from chronic pancreatitis.

Early stage chronic pancreatitis is challenging to diagnose, as well, so there remains intrinsic value to confirming an enigmatic diagnosis in the patient with severe, unexplained abdominal pain, where pancreatic disease remains possible.

This technology employs an optical spectroscopy method to more accurately detect cancer and differentiate chronic pancreatitis from normal pancreas. It can be used to interrogate pancreatic tissues during minimally invasive endoscopic procedures or surgery, is portable, rapid, and does not require the administration of exogenous contrast agents to patients.

Applications ¥ Handheld surgical probe or needle-based endoscopic probe to detect chronic pancreatitis and pancreatic adenocarcinoma ¥ Platform for other EUS-FNA diagnostic applications ¥ Platform for tumor margin detection in the pancreas

Advantages ¥ Improved sensitivity and specificity to detect chronic pancreatitis and pancreatic adenocarcinoma ¥ Rapid, real-time feedback; Label-free tissue diagnostics ¥ Quantitative tissue sensing / mapping ¥ Non- or minimally-invasive; Proof of concept in human tissues, in vivo ¥ Patented and patent applications filed

Patent Status: Three Issued U.S. patents (8,239,139; 8,234,078; 8,694,266). A recently filed provisional patent application (worldwide rights available) covers a miniaturized device deployable within an EUS-FNA needle.